RUO Principal

Repositorio Institucional de la Universidad de Oviedo

Ver ítem 
  •   RUO Principal
  • Producción Bibliográfica de UniOvi: RECOPILA
  • Artículos
  • Ver ítem
  •   RUO Principal
  • Producción Bibliográfica de UniOvi: RECOPILA
  • Artículos
  • Ver ítem
    • español
    • English
JavaScript is disabled for your browser. Some features of this site may not work without it.

Listar

Todo RUOComunidades y ColeccionesPor fecha de publicaciónAutoresTítulosMateriasxmlui.ArtifactBrowser.Navigation.browse_issnPerfil de autorEsta colecciónPor fecha de publicaciónAutoresTítulosMateriasxmlui.ArtifactBrowser.Navigation.browse_issn

Mi cuenta

AccederRegistro

Estadísticas

Ver Estadísticas de uso

AÑADIDO RECIENTEMENTE

Novedades
Repositorio
Cómo publicar
Recursos
FAQs

Autonomic involvement in Parkinsonian carriers of PARK2 gene mutations

Autor(es) y otros:
Tijero, Beatriz; Gabilondo, Iñigo; Lezcano, Elena; Teran-Villagrá, Nuria; Llorens, Verónica; Ruiz-Martinez, Javier; Marti-Masso, Jose Felix; Carmona, Mar; Luquin, Maria Rosario; Berganzo, Koldo; Fernández Vega, IvánAutoridad Uniovi; Fernandez, Manuel; Zarranz, Juan José; Gómez-Esteban, Juan Carlos
Palabra(s) clave:

PARK2 mutation

Autonomic dysfunction

postmortem tissue study

Parkinson's disease

Fecha de publicación:
2015-04-23
Citación:
Parkinsonism and Related Disorders, 21(7), p. 717-22 (2015); doi:10.1016/j.parkreldis.2015.04.012
Descripción física:
p. 717-22
Resumen:

Background and objectives: The objective of this study was to assess the presence of autonomic nervous system dysfunction in PARK2 mutation carriers. Patients and methods: We performed a cross-sectional analysis of 8 PARK2 carriers (age: 60.1 ± 12.8 years) and 13 individuals with idiopathic PD (iPD) (age: 59.2 ± 8.9 years). Autonomic dysfunction was measured using the SCOPA-AUT questionnaire, non-invasive autonomic tests and responses of noradrenaline and vasopressin levels to postural changes. Myocardial sympathetic denervation was assessed with metaiodobenzylguanidine (MIBG) scintigraphy. This damage was further investigated in postmortem epicardial tissue of one PARK2 carrier and three control cases (two PD patients and one subject without PD). Results: The prevalence of autonomic symptoms and orthostatic hypotension (OH) was lower in PARK2 mutation carriers than in iPD patients (SCOPA OUT: 3.4 ± 4.8 vs. 14.7 ± 7.2, p < 0.001; OH: present in three iPD patients but none of the PARK2 mutation carriers). Second, sympathetic myocardial denervation was less severe in PARK2 mutation carriers compared to controls, both in MIBG scintigraphy (late H/M uptake ratio: 1.52 ± 0.35 vs. 1.32 ± 0.25 p < 0.05) and in postmortem tissue study. Interestingly, axonal alpha-synuclein deposits were absent in epicardial tissue of the PARK2 mutation carrier while they were present in the two PD patients. Interpretation: Our study supports the view that autonomic nervous system dysfunction and myocardial sympathetic denervation are less pronounced in PARK2 mutation carriers than in individuals with iPD, suggesting that the involvement of small peripheral sympathetic nerve fibers is a minor pathological hallmark in PARK2 carriers.

Background and objectives: The objective of this study was to assess the presence of autonomic nervous system dysfunction in PARK2 mutation carriers. Patients and methods: We performed a cross-sectional analysis of 8 PARK2 carriers (age: 60.1 ± 12.8 years) and 13 individuals with idiopathic PD (iPD) (age: 59.2 ± 8.9 years). Autonomic dysfunction was measured using the SCOPA-AUT questionnaire, non-invasive autonomic tests and responses of noradrenaline and vasopressin levels to postural changes. Myocardial sympathetic denervation was assessed with metaiodobenzylguanidine (MIBG) scintigraphy. This damage was further investigated in postmortem epicardial tissue of one PARK2 carrier and three control cases (two PD patients and one subject without PD). Results: The prevalence of autonomic symptoms and orthostatic hypotension (OH) was lower in PARK2 mutation carriers than in iPD patients (SCOPA OUT: 3.4 ± 4.8 vs. 14.7 ± 7.2, p < 0.001; OH: present in three iPD patients but none of the PARK2 mutation carriers). Second, sympathetic myocardial denervation was less severe in PARK2 mutation carriers compared to controls, both in MIBG scintigraphy (late H/M uptake ratio: 1.52 ± 0.35 vs. 1.32 ± 0.25 p < 0.05) and in postmortem tissue study. Interestingly, axonal alpha-synuclein deposits were absent in epicardial tissue of the PARK2 mutation carrier while they were present in the two PD patients. Interpretation: Our study supports the view that autonomic nervous system dysfunction and myocardial sympathetic denervation are less pronounced in PARK2 mutation carriers than in individuals with iPD, suggesting that the involvement of small peripheral sympathetic nerve fibers is a minor pathological hallmark in PARK2 carriers.

URI:
https://hdl.handle.net/10651/76226
DOI:
10.1016/j.parkreldis.2015.04.012
Colecciones
  • Artículos [37541]
Ficheros en el ítem
Métricas
Compartir
Exportar a Mendeley
Estadísticas de uso
Estadísticas de uso
Metadatos
Mostrar el registro completo del ítem
Página principal Uniovi

Biblioteca

Contacto

Facebook Universidad de OviedoTwitter Universidad de Oviedo
El contenido del Repositorio, a menos que se indique lo contrario, está protegido con una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Creative Commons Image